Here is the design of a clinical trial:

Official Title: Effect of Medically Lowering Intraocular Pressure in Glaucoma Suspects With High Myopia: A Randomized Controlled Trial

Included conditions:
- Glaucoma, Suspect
- High Myopia

Study Armgroups:
- {'label': 'Intervention arm', 'type': 'EXPERIMENTAL', 'description': 'medical reduction of IOP by eyedrops', 'interventionNames': ['Drug: IOP lowering eye drops']}
- {'label': 'control arm', 'type': 'NO_INTERVENTION', 'description': 'follow up without medication'}

Interventions:
- {'type': 'DRUG', 'name': 'IOP lowering eye drops', 'description': '1. Latanoprost 0.005% eye drops will be the first choice. If an IOP reduction of 20% is not achieved within three months, timolol 0.5% will be added as second medication. If an IOP reduction of 20% is then not achieved, alphagan 0.2% or alphagan-P 0.15% will be added. If an IOP reduction of 20% is then not achieved, the individual will be excluded from the study.\n2. If necessary, latanoprost will be switched to other prostaglandin eye drops, alphagan (or alphagan-P) will be switched to brinzolamide 1% eye drops.\n3. If necessary, latanoprost and timolol will be switched to Xalacom eye drops, timolol and alphagan will be switched to Combigan eye drops, timolol and brinzolamide will be switched to Azarga eye drops.\n4. Once daily in the evening for prostaglandin eye drops, and twice daily for other eye drops.', 'armGroupLabels': ['Intervention arm']}

Primary Outcomes:
- {'measure': 'The number of subjects whose visual filed progressed during the follow up', 'timeFrame': '36 months'}

Please estimate the sample size based on the assumption: 
A two-sided significance level of 0.05, 90% power, and a 20% attrition rate over 3 years.
Sample size {14}
        The sample size calculation was based on the primary outcome, the incidence of glaucoma suspect progression over 36âmonths. The hypothesis was formed according to the findings of the relevant publications. The Early Manifest Glaucoma Trial (EMGT) [17, 20] reported that the 2-year progression rate among patients with early primary open-angle glaucoma was 24% in the non-medication group and 11% in the medication group. The United Kingdom Glaucoma Treatment Study (UKGTS) [21, 22] reported that the 2-year progression rate of patients with early and middle primary open-angle glaucoma was 25.6% in the placebo group and 15.2% in the IOP-lowering medication group. The risk of progressing to open-angle glaucoma among patients with HM was nearly five times that of the non-myopia individuals [5, 6]. In this study, it is expected that the IOP-lowering medication can reduce the 36-month progression rate of GSHM by 18%, assuming an incidence of 30% in the control group. At a two-sided significance level of 0.05, in order to achieve 90% power, 106 participants will be required in each study group. Considering a 20% of attrition rate over 3Â years, the final sample size will be 132 participants per group and a total 264 for the two groups [23â27]. The sample size was calculated using PASS 11.0 software (NCSs, LLC, Kaysville, UT, USA).